J. A. Meyerhardt

1.5k total citations · 1 hit paper
24 papers, 1.2k citations indexed

About

J. A. Meyerhardt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. A. Meyerhardt has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in J. A. Meyerhardt's work include Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. A. Meyerhardt is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Gastric Cancer Management and Outcomes (7 papers) and Cancer Treatment and Pharmacology (6 papers). J. A. Meyerhardt collaborates with scholars based in United States and Canada. J. A. Meyerhardt's co-authors include Charles S. Fuchs, Shuji Ogino, Gregory J. Kirkner, Tomonori Kawasaki, Massimo Loda, Edward L. Giovannucci, Katsuhiko Nosho, Thomas A. Abrams, Peter C. Enzinger and Pankaj Bhargava and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Gut.

In The Last Decade

J. A. Meyerhardt

23 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

2008 594 citations Shuji Ogino, Katsuhiko Nosho et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. A. Meyerhardt United States	10	852	540	313	303	260	24	1.2k
Yasuyuki Miyakura Japan	16	704 0.8×	503 0.9×	204 0.7×	340 1.1×	256 1.0×	93	1.2k
Christina Therkildsen Denmark	15	516 0.6×	527 1.0×	171 0.5×	158 0.5×	293 1.1×	46	908
Al B. Benson United States	5	784 0.9×	495 0.9×	122 0.4×	193 0.6×	132 0.5×	7	970
Eugene Hsieh Canada	14	1.3k 1.5×	1.2k 2.2×	255 0.8×	233 0.8×	402 1.5×	29	1.8k
Pierre Bohanes United States	16	592 0.7×	116 0.2×	266 0.8×	350 1.2×	205 0.8×	52	1.0k
Regina Esser Germany	14	921 1.1×	345 0.6×	472 1.5×	115 0.4×	170 0.7×	39	1.1k
J. Kalmus Germany	10	708 0.8×	360 0.7×	294 0.9×	117 0.4×	114 0.4×	22	1.0k
Chueh‐Chuan Yen Taiwan	19	386 0.5×	173 0.3×	377 1.2×	203 0.7×	73 0.3×	58	930
Lan L. Gellert United States	17	275 0.3×	186 0.3×	191 0.6×	409 1.3×	212 0.8×	30	959
Jaideep Sandhu United States	12	724 0.8×	338 0.6×	213 0.7×	149 0.5×	268 1.0×	29	929

Countries citing papers authored by J. A. Meyerhardt

Since Specialization

Citations

This map shows the geographic impact of J. A. Meyerhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. A. Meyerhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. A. Meyerhardt more than expected).

Fields of papers citing papers by J. A. Meyerhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. A. Meyerhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. A. Meyerhardt. The network helps show where J. A. Meyerhardt may publish in the future.

Co-authorship network of co-authors of J. A. Meyerhardt

This figure shows the co-authorship network connecting the top 25 collaborators of J. A. Meyerhardt. A scholar is included among the top collaborators of J. A. Meyerhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. A. Meyerhardt. J. A. Meyerhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Corcoran, Ryan B., Ju Tian, J. Chen, et al.. (2022). SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients. Annals of Oncology. 33. S373–S373.

Abrams, Thomas A., Gary Meyer, Deborah Schrag, et al.. (2014). Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer. JNCI Journal of the National Cancer Institute. 106(2). djt371–djt371. 82 indexed citations

Ogino, Shuji, J. A. Meyerhardt, Anthony T.�C. Chan, et al.. (2011). Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803. JNCI Journal of the National Cancer Institute. 103(20). 1540–1551. 71 indexed citations

Chan, Jennifer A., Lawrence S. Blaszkowsky, Peter C. Enzinger, et al.. (2011). A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Annals of Oncology. 22(6). 1367–1373. 83 indexed citations

Meyerhardt, J. A., Deborah Schrag, Matthew H. Kulke, et al.. (2010). Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 28(15_suppl). e14055–e14055. 1 indexed citations

Blaszkowsky, Lawrence S., Thomas A. Abrams, Rebecca A. Miksad, et al.. (2010). Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 28(15_suppl). e14542–e14542. 9 indexed citations

Zhu, Andrew X., J. A. Meyerhardt, Lawrence S. Blaszkowsky, et al.. (2009). Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). Journal of Clinical Oncology. 27(15_suppl). 4578–4578. 4 indexed citations

Ogino, Shuji, Katsuhiko Nosho, Gregory J. Kirkner, et al.. (2008). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 58(1). 90–96. 594 indexed citations breakdown →

Wolpin, Brian M., Aram F. Hezel, D. P. Ryan, et al.. (2008). Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 26(15_suppl). 4614–4614. 9 indexed citations

10.

Meyerhardt, J. A., Keith Stuart, Christiane Fuchs, et al.. (2007). Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Annals of Oncology. 18(7). 1185–1189. 63 indexed citations

11.

Ogino, Shuji, Tomonori Kawasaki, Gregory J. Kirkner, et al.. (2007). Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 56(11). 1564–1571. 85 indexed citations

12.

Meyerhardt, J. A., Donna Niedzwiecki, Donna Hollis, et al.. (2007). The impact of dietary patterns on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. Journal of Clinical Oncology. 25(18_suppl). 4019–4019. 1 indexed citations

13.

Blaszkowsky, Lawrence S., David P. Ryan, Craig C. Earle, et al.. (2007). A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 25(18_suppl). 15080–15080. 9 indexed citations

14.

Clark, Jeffrey W., J. A. Meyerhardt, D. Sahani, et al.. (2007). Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. Journal of Clinical Oncology. 25(18_suppl). 4625–4625. 10 indexed citations

15.

Kulke, Matthew H., Keith Stuart, Craig C. Earle, et al.. (2006). A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology. 24(18_suppl). 4044–4044. 68 indexed citations

16.

Zhu, Andrew X., Lawrence S. Blaszkowsky, Peter C. Enzinger, et al.. (2006). Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Journal of Clinical Oncology. 24(18_suppl). 14096–14096. 9 indexed citations

17.

Blaszkowsky, Lawrence S., D. P. Ryan, J. W. Clark, et al.. (2005). A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). 4099–4099. 24 indexed citations

18.

Meyerhardt, J. A., Peter C. Enzinger, D. P. Ryan, et al.. (2004). Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 22(14_suppl). 3580–3580. 2 indexed citations

19.

Sargent, Daniel J., J. A. Meyerhardt, Rajesh Ramanathan, et al.. (2004). Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741. Journal of Clinical Oncology. 22(14_suppl). 3521–3521. 3 indexed citations

20.

Meyerhardt, J. A. & Christine Fuchs. (2002). Chemotherapy options for gastric cancer. Seminars in Radiation Oncology. 12(2). 176–186. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact